Advances in antiplatelet therapy for acute coronary syndromes.

Postgraduate medical journal 20120701

Synthesis of N6-alkyl(aryl)-2-alkyl(aryl)thioadenosines as antiplatelet agents.

European journal of medicinal chemistry 20120701

Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials.

Journal of thrombosis and thrombolysis 20120701

Short-acting P2Y12 blockade to reduce platelet dysfunction and coagulopathy during experimental extracorporeal circulation and hypothermia.

British journal of anaesthesia 20120601

Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial.

American heart journal 20120501

Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction.

American heart journal 20120201

Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial.

JAMA 20120118

Thienopyridines and other ADP-receptor antagonists.

Handbook of experimental pharmacology 20120101

The P2Y(12) antagonists, 2MeSAMP and cangrelor, inhibit platelet activation through P2Y(12)/G(i)-dependent mechanism.

PloS one 20120101

BF061, a novel antiplatelet and antithrombotic agent targeting P2Y₁₂ receptor and phosphodiesterase.

Thrombosis and haemostasis 20111201

Nucleotides control the excitability of sensory neurons via two P2Y receptors and a bifurcated signaling cascade.

Pain 20110801

Beyond aspirin and clopidogrel: is there a need for additional antiplatelet therapy in ACS?

Current cardiology reports 20110801

[ADP receptor blockers: new insights in the therapy and prophylaxis of ischemic heart disease].

Deutsche medizinische Wochenschrift (1946) 20110701

[Myocardial infarction: Role of new antiplatelet agents].

Presse medicale (Paris, France : 1983) 20110601

[Update on anti-platelet therapy].

Deutsche medizinische Wochenschrift (1946) 20110601

[New approaches and indications for the analysis of platelet function in cardiology].

Hamostaseologie 20110502

High residual platelet reactivity on standard clopidogrel maintenance dose predicts increased responsiveness to the double-standard dose in an assay-dependent manner.

Thrombosis and haemostasis 20110501

Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate.

Thrombosis and haemostasis 20110501

Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors.

Thrombosis and haemostasis 20110501

Comparison of the VASP assay and platelet aggregometry in the evaluation of platelet P2Y12 receptor blockade.

Polskie Archiwum Medycyny Wewnetrznej 20110401

[Recent advances on the studies of the platelet's inhibition and aggregation. State of the art of new P2Y12 antagonists].

Recenti progressi in medicina 20110401

Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist.

Arteriosclerosis, thrombosis, and vascular biology 20110201

The new INNOVANCE® PFA P2Y cartridge is sensitive to the detection of the P2Y₁₂ receptor inhibition.

Platelets 20110101

Mode of action of P2Y(12 ) antagonists as inhibitors of platelet function.

Thrombosis and haemostasis 20110101

P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.

Platelets 20110101

Platelet adhesion and degranulation induce pro-survival and pro-angiogenic signalling in ovarian cancer cells.

PloS one 20110101

Nerve injury-activated microglia engulf myelinated axons in a P2Y12 signaling-dependent manner in the dorsal horn.

Glia 20101115

SCH 602539, a protease-activated receptor-1 antagonist, inhibits thrombosis alone and in combination with cangrelor in a Folts model of arterial thrombosis in cynomolgus monkeys.

Arteriosclerosis, thrombosis, and vascular biology 20101101

Mutational analysis of residues important for ligand interaction with the human P2Y(12) receptor.

European journal of pharmacology 20101010

State of the art of new P2Y12 antagonists.

Internal and emergency medicine 20101001

Enhanced platelet reactivity and thrombosis in Apoe-/- mice exposed to cigarette smoke is attenuated by P2Y12 antagonism.

Thrombosis research 20101001

BF0801, a novel adenine derivative, inhibits platelet activation via phosphodiesterase inhibition and P2Y12 antagonism.

Thrombosis and haemostasis 20101001

P2Y13 receptor is critical for reverse cholesterol transport.

Hepatology (Baltimore, Md.) 20101001

Update on the clinical development of cangrelor.

Expert review of cardiovascular therapy 20100801

Antagonism of P2Y12 or GPIIb/IIIa receptors reduces platelet-mediated myocardial injury after ischaemia and reperfusion in isolated rat hearts.

Thrombosis and haemostasis 20100701

[Novel agents in antiplatelet therapy].

Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 20100701

Frontal affinity chromatography-mass spectrometry useful for characterization of new ligands for GPR17 receptor.

Journal of medicinal chemistry 20100513

Two-pore potassium ion channels are inhibited by both G(q/11)- and G(i)-coupled P2Y receptors.

Molecular and cellular neurosciences 20100401

Platelet inhibition with cangrelor.

The New England journal of medicine 20100318

Platelet inhibition with cangrelor.

The New England journal of medicine 20100318

Antiplatelet therapy: cangrelor for ACS-lessons from the CHAMPION trials.

Nature reviews. Cardiology 20100301

Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases.

British journal of pharmacology 20100201

The influence of variation in the P2Y12 receptor gene on in vitro platelet inhibition with the direct P2Y12 antagonist cangrelor.

Thrombosis and haemostasis 20100201

Testing a new approach for rapid and reversible platelet inhibition during percutaneous coronary intervention among patients with acute coronary syndrome.

Hospital practice (1995) 20100201

Emerging P2Y12 receptor antagonists: role in coronary artery disease.

Current vascular pharmacology 20100101

Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist.

Journal of clinical pharmacology 20100101

Prostacyclin receptor stimulation facilitates detection of human platelet P2Y(12) receptor inhibition by the PFA-100 system.

Platelets 20100101

Platelet inhibition with cangrelor in patients undergoing PCI.

The New England journal of medicine 20091210

Intravenous platelet blockade with cangrelor during PCI.

The New England journal of medicine 20091210

Cangrelor - a champion lost in translation?

The New England journal of medicine 20091210

New antiplatelet agents: why they are needed.

European journal of internal medicine 20091201

Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?

Medical science monitor : international medical journal of experimental and clinical research 20091201

Cangrelor: a review on its mechanism of action and clinical development.

Expert review of cardiovascular therapy 20091001

Cangrelor: a novel P2Y12 receptor antagonist.

Expert opinion on investigational drugs 20090801

New P2Y12 blockers.

Journal of thrombosis and haemostasis : JTH 20090701

The P2Y12 antagonists, 2-methylthioadenosine 5'-monophosphate triethylammonium salt and cangrelor (ARC69931MX), can inhibit human platelet aggregation through a Gi-independent increase in cAMP levels.

The Journal of biological chemistry 20090612

Measurement of platelet P-selectin for remote testing of platelet function during treatment with clopidogrel and/or aspirin.

Platelets 20090601

Mechanism of activation and functional role of protein kinase Ceta in human platelets.

The Journal of biological chemistry 20090515

New antiplatelet drugs: beyond aspirin and clopidogrel.

International journal of clinical practice 20090501

Streamlining the design of promising clinical trials: in-vitro testing of antithrombotic regimens and multiple agonists of platelet activation.

Coronary artery disease 20090301

Advances in antiplatelet therapy: agents in clinical development.

The American journal of cardiology 20090202

Cangrelor attenuates coated-platelet formation.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 20090101

RhoA/ROCK I signalling downstream of the P2Y13 ADP-receptor controls HDL endocytosis in human hepatocytes.

Cellular signalling 20090101

Current problems, new opportunities and future directions of anti-platelet therapy - increasing role of novel antiplatelet agents in cardiovascular diseases.

Recent patents on cardiovascular drug discovery 20090101

Novel antiplatelet agents in development: prasugrel, ticagrelor, and cangrelor and beyond.

American journal of therapeutics 20090101

Update on antiplatelet therapy in acute coronary syndromes: what do new drugs bring into clinical practice?

American journal of cardiovascular drugs : drugs, devices, and other interventions 20090101

Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future.

Nature clinical practice. Cardiovascular medicine 20081201

DG-041 inhibits the EP3 prostanoid receptor--a new target for inhibition of platelet function in atherothrombotic disease.

Platelets 20081201

Involvement of basic amino acid residues in transmembrane regions 6 and 7 in agonist and antagonist recognition of the human platelet P2Y(12)-receptor.

Biochemical pharmacology 20081115

Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy.

Thrombosis and haemostasis 20081101

Future prospects in anti-platelet therapy: a review of potential P2Y12 and thrombin receptor antagonists.

Recent patents on cardiovascular drug discovery 20081101

Pharmacology of emerging novel platelet inhibitors.

American heart journal 20080801

Clinical overview of promising nonthienopyridine antiplatelet agents.

American heart journal 20080801

Detection of P2Y(14) protein in platelets and investigation of the role of P2Y(14) in platelet function in comparison with the EP(3) receptor.

Thrombosis and haemostasis 20080801

The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function.

Journal of thrombosis and haemostasis : JTH 20080701

Antiplatelet therapy in acute coronary syndromes.

Current cardiology reports 20080701

Multiple electrode aggregometry and P2Y(12) antagonists.

Thrombosis and haemostasis 20080601

Akt activation is involved in P2Y12 receptor-mediated chemotaxis of microglia.

Journal of neuroscience research 20080515

P2Y12 receptors in spinal microglia are required for neuropathic pain after peripheral nerve injury.

The Journal of neuroscience : the official journal of the Society for Neuroscience 20080507

The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses.

Platelets 20080301

Acyl derivatives of coenzyme A inhibit platelet function via antagonism at P2Y1 and P2Y12 receptors: a new finding that may influence the design of anti-thrombotic agents.

Platelets 20080301

Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect.

Thrombosis research 20080101

GPR17: molecular modeling and dynamics studies of the 3-D structure and purinergic ligand binding features in comparison with P2Y receptors.

BMC bioinformatics 20080101

Enhanced platelet aggregation and activation under conditions of hypothermia.

Thrombosis and haemostasis 20071201

Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial.

American heart journal 20071001

Influence of preparative procedures on assay of platelet function and apparent effects of antiplatelet agents.

The American journal of cardiology 20070815

New antiplatelet therapies for acute coronary syndromes.

Current cardiology reports 20070701

Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin.

Journal of thrombosis and haemostasis : JTH 20070301

Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.

Thrombosis and haemostasis 20070301

Platelet P2 receptors: old and new targets for antithrombotic drugs.

Expert review of cardiovascular therapy 20070101

ADP receptor antagonism: what's in the pipeline?

American journal of cardiovascular drugs : drugs, devices, and other interventions 20070101

Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor.

Thrombosis and haemostasis 20061201

Aspirin and clopidogrel resistance: consideration and management.

Journal of interventional cardiology 20061001

Effects on blood compatibility in vitro by combining a direct P2Y12 receptor inhibitor and heparin coating of stents.

Platelets 20060801

Critical role of ADP interaction with P2Y12 receptor in the maintenance of alpha(IIb)beta3 activation: association with Rap1B activation.

Journal of thrombosis and haemostasis : JTH 20060601

Can the PFA-100 be modified to detect P2Y12 inhibition?

Journal of thrombosis and haemostasis : JTH 20060601

Cangrelor for treatment of coronary thrombosis.

The Annals of pharmacotherapy 20060501

P2Y12 receptor-mediated potentiation of thrombin-induced thromboxane A2 generation in platelets occurs through regulation of Erk1/2 activation.

Journal of thrombosis and haemostasis : JTH 20060301

Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.

American heart journal 20060301

Evaluation of platelet function, a method comparison.

Platelets 20060201

Dependence of platelet thrombus stability on sustained glycoprotein IIb/IIIa activation through adenosine 5'-diphosphate receptor stimulation and cyclic calcium signaling.

Journal of the American College of Cardiology 20060103

The nucleotide receptor P2Y13 is a key regulator of hepatic high-density lipoprotein (HDL) endocytosis.

Cellular and molecular life sciences : CMLS 20051101

Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.

Platelets 20051101

Evidence that the purinergic receptor P2Y12 potentiates platelet shape change by a Rho kinase-dependent mechanism.

Platelets 20051101

Metabotropic P2Y1 receptors inhibit P2X3 receptor-channels in rat dorsal root ganglion neurons.

European journal of pharmacology 20051003

P2Y12 ADP receptor-dependent tyrosine phosphorylation of proteins of 27 and 31 kDa in thrombin-stimulated human platelets.

Thrombosis and haemostasis 20050501

Preclinical and clinical studies with selective reversible direct P2Y12 antagonists.

Seminars in thrombosis and hemostasis 20050401

P2Y receptor antagonists in thrombosis.

Current opinion in investigational drugs (London, England : 2000) 20050301

Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes.

Platelets 20050301

P2Y12 receptors play a significant role in the development of platelet microaggregation in patients with diabetes.

The Journal of clinical endocrinology and metabolism 20050201

Regulation of tissue factor-induced coagulation and platelet aggregation in flowing whole blood.

Thrombosis and haemostasis 20050101

Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases.

Journal of thrombosis and haemostasis : JTH 20050101

Potentiation of platelet aggregation by heparin in human whole blood is attenuated by P2Y12 and P2Y1 antagonists but not aspirin.

Thrombosis research 20050101

Investigation of the PADA as a method for monitoring GPIIb/IIIa inhibitors and other antiplatelet agents.

Seminars in thrombosis and hemostasis 20050101

Autoinhibition of transmitter release from PC12 cells and sympathetic neurons through a P2Y receptor-mediated inhibition of voltage-gated Ca2+ channels.

The European journal of neuroscience 20041201

P2Y12 receptor stimulation inhibits beta-adrenergic receptor-induced differentiation by reversing the cyclic AMP-dependent inhibition of protein kinase B.

Journal of neurochemistry 20040401

Costimulation of the Gi-coupled ADP receptor and the Gq-coupled TXA2 receptor is required for ERK2 activation in collagen-induced platelet aggregation.

FEBS letters 20040102

Inhibition of ADP-induced intracellular Ca2+ responses and platelet aggregation by the P2Y12 receptor antagonists AR-C69931MX and clopidogrel is enhanced by prostaglandin E1.

Cell calcium 20040101

Pharmacodynamic profile of antiplatelet agents: marked differences between single versus costimulation with platelet activators.

Thrombosis research 20040101

Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity.

Arteriosclerosis, thrombosis, and vascular biology 20031001

Potential value of triple antiplatelet therapy for secondary stroke prevention.

Stroke 20031001

Effects of inhibition of P2Y(1) and P2Y(12) on whole blood clotting, coagulum elasticity and fibrinolysis resistance studied with free oscillation rheometry.

Thrombosis research 20030315

In vivo blockade of platelet ADP receptor P2Y12 reduces embolus and thrombus formation but not thrombus stability.

Arteriosclerosis, thrombosis, and vascular biology 20030301

Advantages of fast-acting ADP receptor blockade in ischemic heart disease.

Arteriosclerosis, thrombosis, and vascular biology 20030201

Blockade of the platelet P2Y12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model.

Arteriosclerosis, thrombosis, and vascular biology 20030201

A selective role for phosphatidylinositol 3,4,5-trisphosphate in the Gi-dependent activation of platelet Rap1B.

The Journal of biological chemistry 20030103

The effects of GPIIb-IIIa antagonists and a combination of three other antiplatelet agents on platelet-leukocyte interactions.

Current medical research and opinion 20030101

Effects of the NHE-1 inhibitor cariporide alone or together with the P2Y12 antagonist AR-C 69331 MX on CD62p expression and formation of platelet-leukocyte aggregates.

Thrombosis research 20030101

Agonist concentration-dependent differential responsivity of a human platelet purinergic receptor: pharmacological and kinetic studies of aggregation, deaggregation and shape change responses mediated by the purinergic P2Y1 receptor in vitro.

Platelets 20030101

Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease.

Platelets 20021101

Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin.

Thrombosis and haemostasis 20020901

Functional significance of adenosine 5'-diphosphate receptor (P2Y(12)) in platelet activation initiated by binding of von Willebrand factor to platelet GP Ibalpha induced by conditions of high shear rate.

Circulation 20020528

Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction.

Clinical therapeutics 20020501

A Gi-dependent pathway is required for activation of the small GTPase Rap1B in human platelets.

The Journal of biological chemistry 20020405

Role of ADP receptor P2Y(12) in platelet adhesion and thrombus formation in flowing blood.

Arteriosclerosis, thrombosis, and vascular biology 20020401

Role of the PAR4 thrombin receptor in stabilizing platelet-platelet aggregates as revealed by a patient with Hermansky-Pudlak syndrome.

Thrombosis and haemostasis 20020401

Differential regulation of Rho and Rac through heterotrimeric G-proteins and cyclic nucleotides.

The Journal of biological chemistry 20011221

Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow.

Blood 20011201

Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro.

British journal of pharmacology 20010901

Extracellular ATP or ADP induce chemotaxis of cultured microglia through Gi/o-coupled P2Y receptors.

The Journal of neuroscience : the official journal of the Society for Neuroscience 20010315

Activation of Gi-coupled receptors releases a tonic state of inhibited platelet aggregation.

Platelets 20010301

Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes.

Thrombosis and haemostasis 20010301

ADP receptor antagonists inhibit platelet aggregation induced by the chemokines SDF-1, MDC and TARC.

FEBS letters 20010209

Cangrelor AstraZeneca.

Current opinion in investigational drugs (London, England : 2000) 20010201

The medicinal chemistry of the P2 receptor family.

Progress in medicinal chemistry 20010101